- ImmunoCellular announced that its proprietary method for manufacturing ICT-107, its lead dendritic cell (DC) based vaccine for the treatment of glioblastoma multiforme (GBM), has demonstrated meaningfully enhanced efficiency, consistency and convenience, compared to other methods for producing DC-based immunotherapies.
- The manufacturing method employs a closed-bag system designed to produce highly potent DCs from white blood cells (WBCs) collected from patients, and for subsequently cryopreserving the DCs for future vaccine treatments.
- The process has also been optimized to produce high levels of certain cytokines that play a key role in initiating immune response.
- Despite variability in cell compositions collected from various patients, the product consistently met the purity and viability criteria reviewed by the FDA.
The final manufacturing process is not expected to require significant changes prior to eventual commercialization. IMUC is working with Progenitor Cell Therapy (PCT) / NeoStem (NBS) for manufacturing.
Daily Dose Conclusion: IMUC looks like a compelling value given the phase 1 data, the manufacturing and the progress the company has made this year. We also like the fact that IMUC did raise capital earlier this year too.